# US 2025/0235486 A1 · Method of Producing Insulin-Producing Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0235486 A1
- Document ID: US20250235486A1
- Status: Published application
- Kind: A1
- Application number: 18/861,161
- Filed: 2023-04-28
- Published: 2025-07-24
- Earliest claimed: 2022-04-29
- Applicants: Monash University
- Inventors: Assam El-Osta; Keith Al-Hasani; Ishant Khurana; Harikrishnan Kaipananickal; Scott Stuart Maxwell; Jun Okabe; Safiya Naina Marikar
- Web page: https://patentgrep.com/patent/US20250235486A1

## CPC

- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 31/365: Lactones
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- C12N 5/0676: {Pancreatic cells}
- C07D 401/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 493/22: in which the condensed system contains four or more hetero rings
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/72: Transferases [EC 2.]
- C12N 2506/22: from pancreatic cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to methods and uses for producing an insulin-producing cell from a pancreatic exocrine cell comprising contacting the pancreatic exocrine cell with an inhibitor of EZH2. The present invention also relates to methods and uses for preventing or treating a disease involving dysfunctional insulin production.

## Claims

### Claim 1

A method of producing an insulin-producing cell from a pancreatic exocrine cell, the method comprising:
contacting a pancreatic exocrine cell, or a cell population comprising a pancreatic exocrine cell, with an inhibitor of EZH2 for a sufficient time and under conditions to allow generation of an insulin-producing cell from the pancreatic exocrine cell,
thereby producing an insulin-producing cell, or a cell population comprising an insulin-producing cell.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the insulin-producing cell is characterised by increased expression of one or more pancreatic progenitor markers, relative to a pancreatic exocrine cell that has not been contacted with the inhibitor of EZH2.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the one or more pancreatic progenitor markers are selected from Pdx1, Ngn3, Sox9 and Sox11.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the insulin-producing cell is characterised by increased expression of one or more β-cell markers, relative to a pancreatic exocrine cell that has not been contacted with the inhibitor of EZH2.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the one or more β-cell markers are selected from Nkx6.1, MafA, Ins hnRNA and Ins.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein the insulin-producing cell is characterised by increased expression of one or more proliferation genes, relative to a pancreatic exocrine cell that has not been contacted with the inhibitor of EZH2.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the one or more proliferation genes comprise Ki67.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method according to any one of claims 1 to 7, wherein the insulin-producing cell is characterised by increased expression of one or more of Pdx1, Ngn3, Sox9, Sox11, Nkx6.1, MafA, Ins, Ins hnRNA and Ki67, relative to a pancreatic exocrine cell that has not been contacted with the inhibitor of EZH2.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1 to 8, wherein the insulin-producing cell is characterised by no change in expression of one or more of the following, relative to a pancreatic exocrine cell that has not been contacted with the inhibitor of EZH2: one or more ductal markers; one or more acinar markers; and one or more glucose-sensor markers.

### Claim 10 (depends on 9)

The method according to claim 9, wherein one or more of the following apply: the one or more ductal markers comprise Ck19; the one or more acinar markers comprise Amy2A; and the one or more glucose-sensor markers comprise Txnip.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1 to 10, wherein the insulin-producing cell is capable of secreting insulin upon stimulation with glucose.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the insulin-producing cell is capable of repeatedly performing glucose stimulated insulin secretion (GSIS).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the insulin-producing cell is a β-cell or a β-cell-like cell.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein the pancreatic exocrine cell is an acinar cell or a ductal cell.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the pancreatic exocrine cell is a ductal cell.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein the cell population comprising a pancreatic exocrine cell comprises or consists of one or both of acinar cells and ductal cells.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the cell population consists of ductal cells.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method according to any one of claim 1 to 17, wherein the pancreatic exocrine cell, or the cell population comprising the pancreatic exocrine cell, is obtained from pancreatic tissue.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the pancreatic tissue comprises or consists of pancreatic exocrine cells.

### Claim 20 (depends on 18, 19)

The method according to claim 18 or claim 19, wherein the pancreatic tissue comprises or consists of mature terminally differentiated pancreatic cells.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 1 to 20, wherein the inhibitor of EZH2 directly inhibits the enzymatic activity of EZH2.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the inhibitor of EZH2 occupies the site for co-substrate S-adenosylmethionine (SAM) in the binding pocket of EZH2.

### Claim 23 (depends on 21, 22)

The method according to claim 21 or claim 22, wherein the inhibitor of EZH2 competes with SAM for binding to EZH2.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound of formula (I):
wherein:
X and Z are selected independently from the group consisting of hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, unsubstituted or substituted (C3-C8)cycloalkyl, unsubstituted or substituted (C3-C8)cycloalkyl-(C1-C8)alkyl or —(C2-C8)alkenyl, unsubstituted or substituted (C5-C8)cycloalkenyl, unsubstituted or substituted (C5-C8)cycloalkenyl-(C1-C8)alkyl or —(C2-C8)alkenyl, (C6-C10)bicycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heterocycloalkyl-(C1—C)alkyl or —(C2-C8)alkenyl, unsubstituted or substituted aryl, unsubstituted or substituted aryl-(C1-C8)alkyl or —(C2-C8)alkenyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroaryl-(C1-C8)alkyl or —(C2-C8)alkenyl, halo, cyano, —CORa, —CO2Ra, —CONRaRb, —CONRaNRaRb, —SRa, —SORa, —SO2Ra, —SO2NRaRb, nitro, NRaRb, NRaC(O)Rb, NRaC(O)NRaRb, —NRaC(O)ORa, —NRaSO2Rb, NRaSO2NRaRb, NRaNRaRb, NRaNRaC(O)Rb, —NRaNRaC(O)NRaRb, —NRaNRaC(O)ORa, —ORa, —OC(O)Ra, and —OC(O)NRaRb;
Y is H or halo;
R1 is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, unsubstituted or substituted (C3-C8)cycloalkyl, unsubstituted or substituted (C3-C8)cycloalkyl-(C1-C8)alkyl or —(C2-C8)alkenyl, unsubstituted or substituted (C5-C8)cycloalkenyl, unsubstituted or substituted (C5-C8)cycloalkenyl-(C1-C8)alkyl or —(C2-C8)alkenyl, unsubstituted or substituted (C6-C10)bicycloalkyl, unsubstituted or substituted heterocycloalkyl or —(C2-C8)alkenyl, unsubstituted or substituted heterocycloalkyl-(C1-C8)alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aryl-(C1-C8)alkyl or —(C2-C8)alkenyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroaryl-(C1-C8)alkyl or —(C2-C8)alkenyl, —CORa, —CO2Ra, —CONRaRb, —CONRaNRaRb;
R2 is hydrogen, (C1-C8)alkyl, trifluoromethyl, alkoxy, or halo, in which said (C1-C8)alkyl maybe substituted with one to two groups selected from: amino, and (C1-C3)alkylamino;
R7 is hydrogen, (C1-C3)alkyl, or alkoxy; R3 is hydrogen, (C1-C8)alkyl, cyano, trifluoromethyl, —NRaRb, or halo;
R6 is selected from the group consisting of hydrogen, halo, (C1-C8)alkyl, (C2-C8)alkenyl, —B(OH)2, substituted or unsubstituted (C2-C8)alkynyl, unsubstituted or substituted (C3-C8)cycloalkyl, unsubstituted or substituted (C3-C8)cycloalkyl-(C1-C8)alkyl, unsubstituted or substituted (C5-Cg)cycloalkenyl, unsubstituted or substituted (C5-C8)cycloalkenyl-(C1-C8)alkyl, (C6-C10)bicycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heterocycloalkyl-(C1-C8)alkyl, unsubstituted or substituted aryl, unsubstituted or substituted aryl-(C1-C8)alkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroaryl-(C1-C8)alkyl, cyano, —CORa, —CO2Ra, —CONRaRb, —CONRaNRaRb, —SRa, —SORa, —SO2Ra, —SO2NRaRb, nitro, —NRaRb, —NRaC(O)Rb, NRaC(O)NRaRb, NRaC(O)ORa, NRaSO2Rb, NRaSO2NRaRb, —NRaNRaRb, —NRaNRaC(O)Rb, —NRaNRaC(O)NRaRb, NRaNRaC(O)ORa, —ORa, —OC(O)Ra, —OC(O)NRaRb;
wherein any (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally substituted by 1, 2 or 3 groups independently selected from the group consisting of —O(C1-C6)alkyl(Rc)1-2, —S(C1-C6)alkyl(Rc)1-2, —(C1-C6)alkyl(Rc)1-2, (C1-C8)alkyl-heterocycloalkyl, (C3-C8)cycloalkyl-heterocycloalkyl, halo, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C5-C8)cycloalkenyl, (C1-C6)haloalkyl, cyano, —CORa, —CO2Ra, —CONRaRb, —SRa, —SORa, —SO2Ra, —SO2NRaRb, nitro, —NRaRb, NRaC(O)Rb, —NRaC(O)NRaRb, —NRaC(O)ORa, NRaSO2Rb, NRaSO2NRaRb, —ORa, —OC(O)Ra, —OC(O)NRaRb, heterocycloalkyl, aryl, heteroaryl, aryl(C1-C4)alkyl, and heteroaryl(C1-C4)alkyl;
wherein any aryl or heteroaryl moiety of said aryl, heteroaryl, aryl(C1-C4)alkyl, or heteroaryl(C1-C4)alkyl is optionally substituted by 1, 2 or 3 groups independently selected from the group consisting of halo, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C5-C8)cycloalkenyl, (C1-C6)haloalkyl, cyano, —CORa, —CO2Ra, —CONRaRb, —SRa, —SORa, —SO2Ra, —SO2NRaRb, nitro, NRaRb, NRaC(O)Rb, NRaC(O)NRaRb, NRaC(O)ORa, —NRaSO2Rb, NRaSO2NRaRb, —ORa, —OC(O)Ra, and —OC(O)NRaRb;
each Ro is independently (C1-C4)alkylamino, —NRaSO2Rb, —SORa, —SO2Ra, —NRaC(O)ORa, —NRaRb, or —CO2Ra;
Ra and Rb are each independently hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C5-C8)cycloalkenyl, (C6-C10)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally substituted by 1, 2 or 3 groups independently selected from halo, hydroxyl, (C1-C4)alkoxy, amino, (C1-C4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, —CO2H, —CO2(C1-C4)alkyl, —CONH2, —CONH(C1-C4)alkyl, —CON((C1-C4)alkyl)((C1-C4)alkyl), —SO2(C1-C4)alkyl, —SO2NH2, —SO2NH(C1-C4)alkyl, or —SO2N((C1-C4)alkyl)((C1-C4)alkyl);
or Ra and Rb taken together with the nitrogen to which they are attached represent a 5-8 membered saturated or unsaturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by 1, 2 or 3 groups independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, amino, (C1-C4)alkylamino, ((C1-C4)alkyl)((C1-C4)alkyl)amino, hydroxyl, oxo, (C1-C4)alkoxy, and (C1-C4)alkoxy(C1-C4)alkyl, wherein said ring is optionally fused to a (C3-C8)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
or Ra and Rb taken together with the nitrogen to which they are attached represent a 6- to 10-membered bridged bicyclic ring system optionally fused to a (C3-C8)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the compound of formula (I) has the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the inhibitor of EZH2 is a compound having the following structure:
or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method according to any one of claims 1 to 32, wherein the method further comprises a step of administering the insulin-producing cell, or the cell population comprising the insulin-producing cell, to an individual.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the pancreatic exocrine cell from which the insulin-producing cell is generated is obtained from the individual.

### Claim 35 (depends on 33, 34)

The method according to claim 33 or claim 34, wherein the individual has diabetes mellitus or is pre-diabetic.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the diabetes mellitus is selected from type 1 diabetes, type 2 diabetes and gestational diabetes.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

An insulin-producing cell, or a cell population comprising an insulin-producing cell, produced by the method according to any one of claims 1 to 36.

### Claim 38

Use of an inhibitor of EZH2 in the manufacture of a composition for producing an insulin-producing cell from a pancreatic exocrine cell.

### Claim 39

An inhibitor of EZH2 for use in producing an insulin-producing cell from a pancreatic exocrine cell.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method for preventing or treating a disease involving dysfunctional insulin production, the method comprising:
administering a cell population comprising an insulin-producing cell according to claim 37 or produced by the method according to any one of claims 1 to 36, to an individual in need thereof,
thereby preventing or treating the disease.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the disease involving dysfunctional insulin production is selected from diabetes mellitus and pre-diabetes.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the diabetes mellitus is selected from type 1 diabetes, type 2 diabetes and gestational diabetes.

### Claim 43 (depends on 40, 41, 42)

The method according to any one of claims 40 to 42, wherein the pancreatic exocrine cell from which the insulin-producing cell of the cell population is generated is from pancreatic tissue obtained from the individual.

### Claim 44 (depends on 40, 41, 42, 43)

The method according to any one of claims 40 to 43, wherein the cell population comprising the insulin-producing cell is delivered to the pancreas of the individual.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

Use of an insulin-producing cell or a cell population comprising an insulin-producing cell according to claim 37 or produced by the method according to any one of claims 1 to 36, in the manufacture of a composition for preventing or treating a disease involving dysfunctional insulin production in an individual.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

An insulin-producing cell or a cell population comprising an insulin-producing cell according to claim 37 or produced by the method according to any one of claims 1 to 36, for use in preventing or treating a disease involving dysfunctional insulin production in an individual.

### Claim 47

A method for preventing or treating a disease involving dysfunctional insulin production, the method comprising:
administering an inhibitor of EZH2 to an individual in need thereof such that the inhibitor of EZH2 contacts a pancreatic exocrine cell of the individual for a sufficient time and under conditions to allow generation of an insulin-producing cell from the pancreatic exocrine cell,
thereby preventing or treating the disease in the individual.

### Claim 48 (depends on 47)

The method according to claim 47, wherein the disease involving dysfunctional insulin production is selected from diabetes mellitus and pre-diabetes.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the diabetes mellitus is selected from type 1 diabetes, type 2 diabetes and gestational diabetes.

### Claim 50 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 47, 48, 49)

The method according to any one of claims 47 to 49, wherein the inhibitor of EZH2 is as defined in any one of claims 21 to 32.

### Claim 51

Use of an inhibitor of EZH2 in the manufacture of a composition for preventing or treating a disease involving dysfunctional insulin production in an individual, wherein the inhibitor of EZH2 contacts a pancreatic exocrine cell of the individual for a sufficient time and under conditions to allow generation of an insulin-producing cell from the pancreatic exocrine cell.

### Claim 52

An inhibitor of EZH2 for use in preventing or treating a disease involving dysfunctional insulin production in an individual, wherein the inhibitor of EZH2 contacts a pancreatic exocrine cell of the individual for a sufficient time and under conditions to allow generation of an insulin-producing cell from the pancreatic exocrine cell.
